In recent years there has been growing recognition of the clinical importance of sarcopenia but there is still a major need for more widespread diagnosis and the development of novel treatment options for this highly prevalent age-related condition. Translational research is key to these aims. Great strides are being made in our scientific understanding of sarcopenia and the challenge now is to translate these advances into better care and treatments for older people. Our CMO Dr. Silke Hüttner will provide a talk on drug development for sarcopenia.

Asia's premier partnering event, focusing on providing new value by business partnering of industry, academia, and government from over the world. Ann Beliën, CEO, will present "Rejuvenate Biomed initiating sarcopenia phase 2 study for its lead candidate as identified through proprietary drug discovery platforms (Series C fundraising)".

LSX World Congress USA will replicate the unique dynamics and high-quality senior audience that has become the hallmark of LSX events around the world. We’ll be gathering North America’s leading Biotech, Medtech and Healthtech CEOs for a 2-day executive conference, in-person 1-2-1 partnering and company showcasing opportunities.

Leaders in the aging and longevity field will describe the latest progress in the molecular, cellular and organismal basis of aging and our search for interventions. Our CSO Dr. Evi Mercken will present preclinical data on RJx-01 in her talk titled "A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia".

The second edition of the Health Innovation Euregion Event is an initiative by Medtronic, Medace, LifetecZONe, the municipality of Maastricht, LIOF, Brightlands, and Rabobank for everyone who supports innovation in health care and life sciences. Dr. Ann Beliën will provide a talk titled "From a Corporate to a Startup: Similarities, differences and lessons learned".

The biannual C. elegans Conference is the premier meeting for C. elegans researchers. Hundreds of presentations cover the full diversity of C. elegans investigations, including genetics, molecular biology, cell biology, development, immunology, physiology, neuroscience, evolution, and more. Rejuvenate Biomed's Lead Scientist Dr. Matthias Rieckher will present the poster titled "A drug development platform from bench to bedside for the treatment of age-related diseases".

The BIO International Convention attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. Dr. Ann Beliën will present Rejuvenate Biomed in Boston.

Bio€quity Europe is the industry’s premier CEO and investor conference. Dr. Ann Beliën will present Rejuvenate Biomed in Dublin.

The event brings together the CEOs and senior decision makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs. Together, they share best practice, forge partnerships and investments - all geared at putting capital and ideas to work to help create the world's future medicines and improve patient outcomes.

Europe's largest partnering conference serving the global biotech industry. The annual international event will host its edition in Basel from 20 to 23 March 2023, expecting over 1,000 companies and more than 2,000 visitors and key decision-makers from across the world.

The ICFSR is the only meeting in the world focused exclusively on all aspects of frailty and sarcopenia. The conference offers a selection of keynote presentations, focused symposia, and peer-reviewed poster and free communications on the latest preclinical and clinical research on the topics of frailty and sarcopenia. Led by an internationally recognized organizing committee, the ICFSR brings together clinical, academics and industry leaders to present and discuss the latest research on frailty and sarcopenia. Dr. Ann Beliën will provide a keynote speech on "how to develop drugs for sarcopenia".

Jointly organized by the US National Academy of Medicine, Hevolution Foundation, King Abdullah International Medical Research Center, and Gulf Health Council, this summit will build on recent conferences in Singapore and Washington, DC, bringing together global and regional leaders across the healthy longevity ecosystem to discuss the healthspan in the Gulf and chart a roadmap for healthy longevity in the region. CEO Dr. Ann Beliën will participate in the panel discussion "Meet the Healthy Longevity Innovators" with Dr. Gregory Bailey (Juvenescence), Dr. Kristen Fortney (BioAge Labs), Dr. Anuj Gaggar (Arrive Bio), Jerry McLaughlin (Life Biosciences), and moderator Dr. William Greene (Hevolution Foundation).

Dr. Ann Beliën was invited to the panel “Extending human lifespan: Therapies to target muscle aging” on January 11. Eric Morgen (BioAge Labs) and panelists Ann Beliën (Rejuvenate Biomed), William Evans (Berkeley/Duke), Carl Morris (Solid Biosciences), and Hanadie Yousef (Juvena Therapeutics) will discuss the challenges and opportunities of longevity biotech.

Mediafin, publisher of De Tijd and L’Echo, is holding the 14th high-level networking event Leaders Meeting @ Paris. This year’s Leaders Meeting focuses on ‘Never waste a good crisis’. What are the best ways of looking after yourself and your organisation in times of global crises? What are the best ways of handling moments of crisis in your own life and your organisation? And how can we, as business, societal or academic leaders, offer solutions in these times of deep geopolitical, climate and economic crisis? Dr. Ann Beliën is invited for an interview on Saturday 19th November at 11:30.

BIO Europe attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts. Rejuvenate will be joining the Belgian Pavilion at BIO Europe.

The Rejuvenation Startup Summit 2022 brought to you by the Forever Healthy Foundation, is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry. Dr. Silke Hüttner will present Rejuvenate Biomed in a company pitch.

On the occasion of BioJapan 2022, the leading partnering event for the biotech and life science industry in Asia, flanders.bio and FIT Tokyo are joining forces for the organisation of a Flemish Biotech and Life Sciences Week in Japan. Japanese pharma companies are intensively looking for licensing opportunities to fill their pipelines. Over the past 15 years, many Flemish companies & organisations have started partnerships with Japanese companies. Rejuvenate will be joining the pavilion at BioJapan 2022, showcasing the Flanders biotech and life science cluster.

Leaders in the aging and longevity field will describe the latest progress in the molecular, cellular and organismal basis of aging and our search for interventions. Rejuvenate Biomed is sponsoring ARDD and a presentation will be given by dr. Ann Beliën.

The European Worm Meeting is hosted by the University of Vienna. It will be an in-person meeting with many opportunities for networking with C. elegans researchers from across Europe and beyond.

This convention will feature 100+ interactive sessions across 4 days covering a variety of therapeutic areas, business development, digital health, patient advocacy, public policy, and next-generation biotherapeutics. Dr. Ann Beliën will join the panel discussion on “Targeting aging to treat chronic disease”. This session will be of broad interest to an audience interested in serving as investors, founders, drug developers, or researchers in the emerging field of longevity-based therapeutics.

Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs. Dr. Ann Beliën will present the company in Milan.

The ICFSR conference was created by Academics with the objective to speed the development of high-quality clinical trials in frail older adults by sharing experiences, success and failure alike, to accelerate the discovery of treatments, prevention methods for healthy aging and prevention of disabilities and dependency in older adults. Dr. Ann Beliën will give a talk on "RJx-01 into the clinic: a first-of-its kind muscle disuse study" on April 21.

The 2nd Euro-Geroscience Conference will provide a forum for open discussion of the current advances and future development in the field. The high-level conference will feature many of the most salient world leaders in the field of geroscience, and will serve to highlight nascent efforts in the field in Europe, and Toulouse in particular. Dr. Ann Beliën will chair session 5: Geroscience and Biotechs Europe - Different approaches, similar goals.

As an international and multidisciplinary organization, the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) seeks to further research on cachexia, sarcopenia and muscle wasting in order to bring practical solutions to healthcare teams worldwide. This year's online conference is expected to be a unique forum for all medical professionals dealing with muscle wasting in their disciplines.

The ICFSR is the only meeting in the world focused exclusively on all aspects of frailty and sarcopenia. The conference offers a selection of keynote presentations, focused symposia, and peer-reviewed poster and free communications on the latest preclinical and clinical research on the topics of frailty and sarcopenia. Led by an internationally recognized organizing committee, the ICFSR brings together clinical, academics and industry leaders to present and discuss the latest research on frailty and sarcopenia.

The cream of the Belgian life sciences community will attend the 17th edition of flanders.bio’s annual knowledge for growth business conference, attracting decision makers from biotech, pharma and medtech, agricultural and chemical industry as well as investors, universities, topnotch research institutes, policymakers and competence providers. Dr. Ann Beliën will be a speaker and panelist in the breakout sessions devoted to Lifestyle, Care & Healthy Ageing, within the track Preventive Medicine.

ARDD is bringing together leaders in the field with the focus on aging research, drug discovery and biomarker development. The 8th Aging Research and Drug Discovery Meeting will take place at the University of Copenhagen, as a hybrid online and in-person conference. Leaders in the aging and longevity field will describe the latest progress in the molecular, cellular and organismal basis of aging and our search for interventions.

Sarcopenia is a growing area of clinical and research activity, and the need for more widespread diagnosis and the development of treatment options is pressing. Translational research is key to these aims. Great strides are being made in our scientific understanding of sarcopenia and muscle disease, and the challenge now is to translate these advances into better care and better treatments for older people. We hope that you will be able to join us and enjoy the opportunity to hear from leaders in this rapidly evolving field to shape the future research agenda.

Bio€quity Europe is the industry’s premier international showcase for financial dealmakers and pharmaceutical executives to assess and network with rising biotechs.

Evidence, Pricing and Access is Europe’s largest congress in market access, pricing and evidence featuring 150 speakers, multiple streams and over 1000 attendees from pharma, biotech and Payers/HTA’s.

The healthy aging consortium, in4care and CT paramedics join their forces in organizing the closing symposium of the Interreg EMR Healthy Aging project. Dr. Ann Beliën will share her thoughts on how a resilient mind in a resilient body can make a difference during aging.

An inspiring event organized by Johnson & Johnson Innovation - JLABS @ BE on how to develop a more inclusive leadership in the workplace during today’s crisis and beyond. Dr. Ann Beliën will participate during the Inclusive Leadership Panel Discussion.

An international showcase of early, growth stage and public life science and health technology companies, Investival Showcase provides an unrivalled opportunity to pitch, profile and connect with investors and partners brought together during the biggest fortnight in European life sciences investment. The company showcases will highlight and promote the most exciting and innovative biotech, medtech, health technology and consumer health companies across Europe and beyond.

The 7th China Healthcare Summit will feature virtual Road Show presentations to showcase private and public biotechs and MedTech companies from China, Asia and the West. This will be a unique opportunity for companies to present to top China investors and biopharma CEOs, as well as domestic and multinational pharma licensing executives. Presenting Companies are hand-picked by BioCentury and BayHelix based on rigorous selection criteria, including investor validation, upcoming milestones, unpartnered assets and innovative science.

The Longevity Leaders World Congress is the definitive global meeting with the mission of extending human health span, delivering healthy ageing and financial wellness in the context of longevity.

Longevity.Technology brings together a stellar group of experts from the longevity field during this 5-day online conference. With so many conferences postponed, this is a great opportunity for speakers to share their latest research, innovations and opinions.

The ICFSR brings together clinical, academics and industry leaders to present and discuss the latest research on frailty and sarcopenia.

The Global Investor Forum facilitates private capital match with promising investment-ready Life Sciences, MedTech, E-health and AI start-ups, scale-ups and tech transfer opportunities. The Global Investor Forum creates a powerful network of leading biomed entrepreneurs, formal and informal investors, physician key-opinion leaders and innovation executives, offering an excellent platform for leading investors, start-up founders and CEO's of innovative companies to discuss investment opportunities, to expand and strengthen business network for future partnerships.

In this workshop, we will present some of the main grants available for life science entrepreneurs in Europe, and we will talk about some of the main pitfalls in finding grants, writing applications and managing grant projects, and show you how to avoid them.

During the conference, you will learn how to create an optimal environment to enable elderly people to benefit from value added medicines and the role of the various healthcare stakeholders in this process. You will learn more about regulatory and legal topics, market access, the future outlook in the digital space of value added medicines and much more. Dr. Ann Beliën will be a panelist in the session on optimizing the regulatory environment for value added medicines.

A series of international meetings will aim to increase and enhance our understanding of geroscience concepts, and to encourage researchers around the globe to integrate these concepts into their research endeavors, in order to accelerate the development of both prevention and intervention strategies. Dr. Ann Beliën will provde a talk on interventions based on aging biology/ physiology

This symposium focuses on understanding how aging happens in the human body. Different insights will be discussed, including the link between aging and genetics/immunology. Dr. Ann Beliën will provide a talk on the challenges of developing healthy aging drugs.

The collaborative gathering of the corporate investment communities for the European life sciences. Rejuvenate Biomed has been chosen by the selection committee to participate as a Next Wave Presenting Company at the 20th Bio€quity Europe. Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial and BD&L community to do business with independently selected Presenting Companies.

The Task Force of the International Conference of Frailty and Sarcopenia Research is a limited group of academic and industry scientists from around the world that met in February 2019 to discuss the current state of biomarker development for frailty and sarcopenia and to explore approaches for establishing clinical meaningfulness and related regulatory considerations.

What types of local or European grants are available for life sciences start-ups? What do you do when it is too late for Venture Capital and too early for Private Equity? What is the best financing strategy when transitioning from a bio-incubator into your own facilities? Are you aware of the existing tax incentives to optimise your business plan? There are so many questions about the best funding & financing strategies from start-up to scale-up and beyond.

The Vlerick Healthcare Conference has become the annual reference in the field taking into account a total healthcare ecosystem perspective. Broaden your network in an inspiring blend of interactive sessions and keynote presentations by top speakers. The Vlerick Healthcare Conference targets all professionals active in healthcare and the life sciences, and everyone simply looking to stay on top of the most important trends in the field.